- Home
- ADPT vs CC Comparison
ADPT vs CC Comparison
Compare ADPT & CC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADPT
- CC
- Stock Information
- Founded
- ADPT 2009
- CC 2014
- Country
- ADPT United States
- CC United States
- Employees
- ADPT N/A
- CC N/A
- Industry
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- CC Major Chemicals
- Sector
- ADPT Health Care
- CC Industrials
- Exchange
- ADPT Nasdaq
- CC Nasdaq
- Market Cap
- ADPT 1.4B
- CC 1.6B
- IPO Year
- ADPT 2019
- CC N/A
- Fundamental
- Price
- ADPT $10.38
- CC $10.74
- Analyst Decision
- ADPT Strong Buy
- CC Buy
- Analyst Count
- ADPT 7
- CC 9
- Target Price
- ADPT $10.57
- CC $17.67
- AVG Volume (30 Days)
- ADPT 1.3M
- CC 3.9M
- Earning Date
- ADPT 07-31-2025
- CC 07-31-2025
- Dividend Yield
- ADPT N/A
- CC 7.77%
- EPS Growth
- ADPT N/A
- CC N/A
- EPS
- ADPT N/A
- CC 0.18
- Revenue
- ADPT $189,527,000.00
- CC $5,788,000,000.00
- Revenue This Year
- ADPT $24.46
- CC $4.91
- Revenue Next Year
- ADPT $20.25
- CC $3.82
- P/E Ratio
- ADPT N/A
- CC $59.73
- Revenue Growth
- ADPT 8.61
- CC N/A
- 52 Week Low
- ADPT $2.99
- CC $9.13
- 52 Week High
- ADPT $10.87
- CC $25.54
- Technical
- Relative Strength Index (RSI)
- ADPT 62.28
- CC 46.57
- Support Level
- ADPT $9.90
- CC $10.44
- Resistance Level
- ADPT $10.85
- CC $11.74
- Average True Range (ATR)
- ADPT 0.48
- CC 0.62
- MACD
- ADPT -0.02
- CC 0.06
- Stochastic Oscillator
- ADPT 68.39
- CC 55.15
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
About CC Chemours Company (The)
The Chemours Co is a provider of chemicals. It delivers customized solutions with a wide range of industrial and specialty chemicals products for various markets including coatings, plastics, refrigeration, air conditioning, etc. The company's operating segments include Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. It generates maximum revenue from the Titanium Technologies segment. The Titanium Technologies segment is a producer of TiO2 pigment, a premium white pigment used to deliver whiteness, brightness, opacity, durability, efficiency, and protection across a variety of applications. Geographically, the company derives a majority of its revenue from North America.